sur IKONISYS (EPA:ALIKO)
Ikonisys SA announces promising annual results for 2025
Ikonisys SA has published its financial results for 2025, marked by a 52.6% increase in operating revenue, reaching €1.64 million. This growth is attributed to the integration of Hospitalex and the rollout of Aliko Scientific's offering. EBITDA also showed a 32.9% improvement, despite a loss of €1.14 million.
The group has focused on developing its integrated oncology diagnostic platform, marked by obtaining a US patent for ACTA technology and launching Urine24. An exclusive distribution agreement with Menarini Diagnostics in Italy complements these advances.
Despite a net loss of 4.2 million euros, Ikonisys strengthened its financial operations and cash position to 1.03 million euros as of December 31, 2025.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de IKONISYS